SEC Form 4 · accession 0001179110-18-011343
RIGEL PHARMACEUTICALS INC · RIGL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eldon C. Mayer III
Officer — EVP & Chief Commercial Officer
Period of report
Sep 10, 2018
Accepted (ET)
Sep 12, 2018 · 7:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001034842
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 10, 2018 | P | 50,000 | $3.2842 | A | 165,000 | D | |
| Common StockF2 | Sep 11, 2018 | P | 50,000 | $3.2268 | A | 215,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is the weighted average price. These shares were purchased in multiple transaction ranging from $3.26 to $3.31. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares purchased at each separate price.
- F2The price reported in Column 4 is the weighted average price. These shares were purchased in multiple transaction ranging from $3.19 to $3.27. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares purchased at each separate price.